SPRYD4

Across TCGA pan-cancer cohorts, SPRYD4 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SPRYD4’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SPRYD4 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SPRYD4 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and PDAC are the cancer types where SPRYD4 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPRYD4 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	−0.828	<.001	12	view →
HNSC	All	All	−0.522	<.001	12	view →
PDAC	Female	All	−0.988	<.001	7	view →
LSCC	Male	II,III,IV	+0.285	<.001	6	view →
COAD	All	II,III,IV	−0.197	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SPRYD4–CCRCC

Open the CCRCC breakdown →